Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt
Joint Authors
al-Kinaai, Najla
Zaghlul, Muhammad Sad
al-Zumur, Husam
Ahmad, Jihad
al-Minawi, Salma
Abd al-Wahhab, Mayy Amr
Fawzi, Muhammad
Rifat, Amal
Sulayman, Suniya
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 30, Issue 1 (31 Jan. 2018), pp.21-26, 6 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2018-01-31
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Aim : The study aims to evaluate survival outcome in newly diagnosed pediatric intermediate risk neuroblastoma patients treated at the Children Cancer Hospital – Egypt and their relation to various clinical and pathological factors.
Methods : The study included stage 3 patients <1.5 years, children 1.5 years or older with stage 3 disease and favorable histopathological features, infants (<1 year) with International Neuroblastoma Staging System(INSS) stage 4 disease, stage 4 children 1–1.5 years with favorable biology, and infants stage 4 s (with unfavorable biologic features).
Patients received systemic chemotherapy, in the form of etoposide and carboplatin alternating with cyclophosphamide, doxorubicin and vincristine, administered at 3-week intervals, with a total of 6 or 8 cycles guided by reaching objective overall response (complete/very good partial/partial response).
Results : The study included 136 patients, 67 males and 69 females.
101 patients had abdominal primary tumors, 28 had mediastinal masss and 7 with masses in the neck; 68% were stage 3 and the remaining (n = 44) had metastatic disease.
The three-year overall survival (OS) and event-free survival (EFS) estimates were 94% ± 2% and 90.9% ± 2.5%, respectively.
OS and EFS by gender, age, pathology and INPC were all statistically not significantly different.
Moreover, OS for patients having surgery versus no surgery (inoperable residual only) was statistically significant (98.4% ± 1.6% & 88.7% ± 5.3%, respectively, p = .034).
Conclusion : A very high rate of survival is currently achievable in patients with intermediate risk neuroblastoma by chemotherapy or chemotherapy and surgery.
In addition to response, our plan is to adopt biologically-based treatment to reduce treatment-induced complications among survivors
American Psychological Association (APA)
al-Zumur, Husam& Ahmad, Jihad& al-Minawi, Salma& al-Kinaai, Najla& Rifat, Amal& Sulayman, Suniya…[et al.]. 2018. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute،Vol. 30, no. 1, pp.21-26.
https://search.emarefa.net/detail/BIM-788948
Modern Language Association (MLA)
al-Zumur, Husam…[et al.]. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute Vol. 30, no. 1 (Jan. 2018), pp.21-26.
https://search.emarefa.net/detail/BIM-788948
American Medical Association (AMA)
al-Zumur, Husam& Ahmad, Jihad& al-Minawi, Salma& al-Kinaai, Najla& Rifat, Amal& Sulayman, Suniya…[et al.]. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute. 2018. Vol. 30, no. 1, pp.21-26.
https://search.emarefa.net/detail/BIM-788948
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 25-26
Record ID
BIM-788948